DePuy Synthes

Raynham,  MA 
United States
http://www.depuyspine.com
  • Booth: 1701, 2811


DePuy Synthes Companies

DePuy Synthes Companies, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com

Brands: CONCORDE® Clear, CONCORDE LIFT, VIPER PRIME System, EXPEDIUM®, PEEK,


 Videos

DePuy Synthes Spine- BioGlass Animation
DePuy Synthes Spine- "Unleash": MIS TLIF Procedural Solution
DePuy Synthes Spine- Concorde LIFT Expandable Cage
DePuy Synthes Spine- Concorde Clear
DePuy Synthes Spine- Expedium Verse

 Press Releases

  •  

    FOR IMMEDIATE RELEASE CONTACTJen Holden

    Jholden2@its.jnj.com

                                                                                                                                     

    DePuy Synthes Unveils CONCORDE LIFT Expandable Interbody Implant as Part of  

    the Company’s Procedural Solution for Minimally Invasive Spine Surgery (MIS), Designed to Enhance Surgical Efficiency

    19 September, Barcelona, SPAIN – DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies** today unveiled the CONCORDE LIFT Expandable Interbody Device to European Surgeons at the EUROSPINE 2018 Meeting, taking place in Barcelona, Spain. The CONCORDE LIFT Implant is designed to treat patients suffering from degenerative disc disease by restoring disc height between vertebrae and completes the Company’s UNLEASH MIS TLIF (Transforaminal Lumbar Interbody Fusion) Procedural Solution.

    MIS is the fastest growing category in spinal fusion surgery and it is estimated that by 2020, half of all spinal fusion procedures will be performed using a minimally invasive approach. 1 MIS TLIF has been associated with lower surgical complications, blood loss, muscular damage and pain, with a faster recovery for patients compared to conventional open spine surgery, yet it is associated with a steep learning curve. 2,3

    This UNLEASH MIS TLIF Procedural Solution was developed by DePuy Synthes Spine to streamline the key stages of the MIS TLIF surgery and additionally includes the CONCORDE Clear MIS Discectomy Device and the VIPER PRIME System for percutaneous pedicle screw insertion:

    • In an anatomic lab study of transforaminal discectomies, surgeons required fewer instrument passes and removed more disc material when using the single-use CONCORDE Clear MIS Discectomy Device compared to standard discectomy tools.4  
    • The CONCORDE LIFT Expandable Interbody Device is inserted once the disc has been cleared. With the reduced insertion size, the surgeon can easily insert and then expand the cage to specifically fit an individual patient’s anatomy without being confined to pre-set intervals.  The streamlined instrumentation, suitable for surgeries with limited intervertebral space, provides tactile feedback during the expansion maneuver and the system offers surgeons the option to back-fill the space with bone graft even after the cage has been fully expanded.
    • The VIPER PRIME System, aimed at efficiency, combines multiple instruments into one screw inserter tool enabling the surgeon to perform percutaneous pedicle screw insertion in a single instrument pass.

    “Minimally Invasive Spine surgery has a lot of immediate and short-term advantages for patients,” said Dr Parajon***, Head of Spine, Neurosurgical department, Hospital University Ramón y Cajal, Madrid; and Head of Neurosurgery, Hospital La Milagrosa.  “I anticipate that the now complete UNLEASH procedural solution will bring great benefit to surgeons and the entire hospital team.”

    This new offering exemplifies the company’s commitment to innovative platforms that are designed to reduce surgical complexity, improve patient outcomes and decrease costs. In an anatomic lab study, the MIS TLIF Solution was shown to reduce the total number of instrument passes by 56% (p=0.086) and showed a reduction in procedure time during disc removal, cage implantation and screw placement by 23% (p=.299) compared to a control group of current product offerings. 5 Based on the early indications of this promising bench top study, DePuy Synthes is investing in a health economics study in addition to a clinical study to evaluate the potential benefits of the UNLEASH MIS TLIF procedural solution as compared to traditional MIS TLIF procedures.

    “With the forthcoming introduction of CONCORDE LIFT, we are delighted to be able to offer the complete UNLEASH Procedural Solution to our customers in the EMEA region,” said Jordy Winters, DePuy Synthes Spine Lead EMEA. “This solution provides us with the technology to serve the needs of our customers by reducing the complexities associated with minimally invasive spine surgery.”

    About the Johnson & Johnson Medical Devices Companies

    As the world’s most comprehensive medical devices business, we are building on a century of experience, leveraging science and technology, to shape the future of healthcare. With unparalleled breadth, depth and reach in surgery, orthopaedics and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life. Learn more about our latest innovations by visiting: https://www.jnjmedicaldevices.com.

    About DePuy Synthes

    DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

    Notes to editors

    The CONCORDE LIFT Expandable Interbody Device is currently being introduced to health care professionals in the Europe, Middle East and Africa (EMEA) region during educational and industry events. Commercial availability of this implant is expected later this year.

    *DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

    **The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.

    *** Dr Parajon is a paid consultant to DePuy Synthes Spine

    This publication is not intended for distribution in the USA

    The third-party trademarks used herein are the trademarks of their respective owners.

    ©Johnson & Johnson Medical Limited. 2018. All rights reserved.

    098508-180910

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding CONCORDE LIFT Expandable Interbody Implant as part of a new procedural solution for minimally invasive spine surgery that enhances surgical efficiency. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes, Inc., any of the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

    ________________________________________________________________________

    1Huang, Tsung-Jen. The State of the Art in Minimally Invasive Spine Surgery. Biomed Res Int. 2017. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350391/.

    2Peng, CW et al. Clinical and radiological outcomes of minimally invasive versus open transforaminal lumbar interbody fusion. Spine (Phila Pa 1976). 2009 Jun 1;34(13):1385-9.

    3 Phan, K et al. Minimally invasive versus open transforaminal lumbar interbody fusion for treatment of degenerative lumbar disease: systematic review and meta analysis. Eur Spine J 24:1017-1030. 2015.

    4 Lavelle, W et al. An In Vitro Study Examining a Novel Suction Curette Device for Lumbar Discectomy Compared with Standard Manual Discectomy. J Neurosurg Spine 26:454-458. 2017.

    5 DePuy Synthes (2018). Comparative ethnographic study of the UNLEASH MIS TLIF solution in a cadaveric lab. (White Paper). 089812-180406. Cadaveric test results may not necessarily be indicative of clinical performance.

  • CONTACT: Kurt Leidner Communications +49 172 4521792
    Matt Stuckley
    Investor Relations
    (732) 524-2617

    Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants


    The Acquired Technology Will Complement Johnson & Johnson Medical Devices Companies’ Advanced Portfolio of Interbody Implants For Both Minimally Invasive and Open Spinal Fusion Surgery


    Norderstedt, Germany – September 12, 2018 – Johnson & Johnson Medical Devices Companies*, through its subsidiary Johnson & Johnson Medical GmbH, announced today the acquisition of Emerging Implant Technologies GmbH (EIT), a privately held manufacturer of 3D-printed titanium interbody implants for spinal fusion surgery, based in Wurmlingen, Germany. The products in this portfolio leverage EIT’s proprietary advanced cellular titanium, which consists of an open and interconnected porous structure designed to allow bone to grow into the implant. As industry leaders across the full range of orthopaedic and spine specialties, the Johnson & Johnson Medical Devices Companies will leverage their global commercial infrastructure to bring EIT’s technologies to patients around the world.

    This acquisition allows DePuy Synthes, the orthopaedics business of Johnson & Johnson, to enhance its comprehensive interbody implant portfolio that includes expandable interbody devices, titanium integrated PEEK technology and now 3D-printed cellular titanium, for both minimally invasive and open spinal surgery. The EIT technology complements DePuy Synthes’ investment in the interbody implant segment in spine, including the recent introductions of the CONCORDE LIFT Expandable Interbody Device, and in the U.S., the PROTI 360°™ Family of Titanium-Integrated Interbody Implants, designed to treat patients with degenerative disc disease.


    “Our goal is to offer a complete portfolio of interbody solutions that provides surgeons with even more options for the treatment of their patients,” said Aldo Denti, Company Group Chairman of DePuy Synthes. “We are excited to welcome the skilled team at EIT, and together, we aspire to bring to market technologies that allow surgeons to perform spinal fusion procedures reliably and with consistent outcomes.”


    This acquisition underscores the companies’ commitment to building an innovative portfolio of spine solutions to improve the standard of care for patients. Moving forward, DePuy Synthes will continue to focus on the spinal disease states with the most potential for surgeons and their patients – degenerative disc disease, deformity and complex cervical – and introduce technologies in the fastest-growing segments within these disease states; specifically, interbody implants, enabling technologies, minimally invasive spine (MIS), and biomaterials.


    Financial terms of the transaction will not be disclosed.


    About DePuy Synthes
    DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

    About the Johnson & Johnson Medical Devices Companies
    As the world's most comprehensive medical devices business, we are building on a century of experience, leveraging science and technology, to shape the future of healthcare. With unparalleled breadth, depth and reach in surgery, orthopaedics and interventional solutions, we're working to profoundly change the way care is delivered. We are in this for life. Learn more about our latest innovations by visiting: https://www.jnjmedicaldevices.com.
    ###


    Cautions Concerning Forward-Looking Statements
    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of EIT. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Medical GmbH, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than expected; challenges inherent in product research and development, especially at an early stage of the development program, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; competition, including technological advances, new products and patents attained by competitors; challenges to patents; and changes to applicable laws and regulations, including tax laws and global health care reforms. In addition, there are risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the technology, products, operations and employees of EIT, as well as the ability to ensure continued development, performance or market growth of EIT products. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.

    *The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, cardiovascular and specialty solutions businesses within Johnson & Johnson’s Medical Devices segment.

  •  

    FOR IMMEDIATE RELEASE CONTACTMeghan Grimaldi 508-828-3246

    Mgrimal4@its.jnj.com

                                                                                                                                     

    DePuy Synthes Expands Spine Portfolio with Nerve Assessment Platform

    Designed to Identify & Avoid Nerves During Spine Surgery

    SENTIO MMG Platform uses differentiated technology to identify nerve status in

    MIS and Open Spine Surgery providing reliable real-time feedback designed to support surgical decision making and potential efficiency during surgery

    Los Angeles – September 26, 2018 – Johnson & Johnson Medical Devices Companies* announced today that DePuy Synthes** is introducing SENTIO MMG, a first-of-its-kind digital mechanomyography platform designed to assess nerve status and identify and avoid peripheral nerves during spine surgery. SENTIO MMG enables motor nerve monitoring for a variety of spine procedures, including non-fusion procedures such as discectomy and both minimally invasive (MIS) and open spinal fusion surgery.  SENTIO MMG is being broadly introduced at the 2018 North America Spine Society Meeting in Los Angeles, California.

    The ability for surgeons to improve how nerves are assessed is an unmet clinical need in spine surgery. Most technologies on the market today rely on multiple needle electrodes in the patient’s arms or legs to locate motor nerves in the cervical and lumbar spine and generate signals. This technology can be problematic due to anesthesia effects, electrical interference, or interpretation challenges. These systems typically require a neuromonitoring specialist to interpret the signals and guide the surgeon. 

    SENTIO MMG consists of a touchscreen tablet, control unit, probes, and smart sensors which can be set up by surgical personnel with a minimal footprint in the operating room. With the launch of SENTIO MMG, DePuy Synthes is enabling surgeons to assess nerve status in a differentiated way. It delivers a patented, smart sensor technology that provides real-time feedback directly to the surgeon on nerve location in the form of visual and audible alerts designed to support surgical decision making and potential efficiency during surgery.

    “The SENTIO MMG System has provided me with a reliable technology to attain nerve mapping during spinal fusion procedures. It is a useful means to assess nerve status intraoperatively while simultaneously making the OR workflow more efficient and decreasing costs for the hospital,” said Frank LaMarca, MD, Neurological Surgeon, Jackson, Michigan***.

    The launch of SENTIO MMG further illustrates DePuy Synthes’ commitment to enhancing its portfolio of enabling technologies in the spine market to help and guide surgeons performing spinal procedures.  

    “The addition of SENTIO MMG to our enabling technologies portfolio will provide value to surgeons performing spine procedures in a variety of care settings, including both hospital and outpatient surgery,” said Nadav Tomer, Worldwide President, Spine, DePuy Synthes. “This platform underscores our commitment to digital technologies that advance care for patients and we believe by embracing solutions such as SENTIO MMG we can help to reduce variability and inefficiency in spine surgery.”

    About the Johnson & Johnson Medical Devices Companies

    As the world’s most comprehensive medical devices business, we are building on a century of experience, leveraging science and technology, to shape the future of healthcare. With unparalleled breadth, depth and reach in surgery, orthopaedics and interventional solutions, we are working to profoundly change the way care is delivered. We are in this for life. Learn more about our latest innovations by visiting: https://www.jnjmedicaldevices.com.

    About DePuy Synthes

    DePuy Synthes provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SENTIO MMG. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

    *The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.

    **DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

    ***Consultant to DePuy Synthes Spine

    099376-180924 DSUS

    ©DePuy Synthes 2018. All rights reserved.